GSK’s new chief executive, Emma Walmsley, will make improving drug research productivity her top priority, focusing the company's pipeline of new drugs.
Walmsley reportedly wants the drugmaker to have fewer but potentially more lucrative new drug launches in future, which means eliminating some experimental drugs in non-core therapy areas, while boosting investments in the more promising fields.
GSK recently announced that its Consumer Healthcare business intends to sell its Horlicks brand in the UK and is proposing to close the associated manufacturing site in Slough where UK product is made, which will result in job losses.
Walmsley will go into detail about her plans for overhauling drug research when she presents second quarter results on July 26.